Literature DB >> 11238496

Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome.

D J Jakubowicz1, M Seppälä, S Jakubowicz, O Rodriguez-Armas, A Rivas-Santiago, H Koistinen, R Koistinen, J E Nestler.   

Abstract

We hypothesized that hyperinsulinemia contributes to early pregnancy loss in the polycystic ovary syndrome by adversely affecting endometrial function and environment. Serum glycodelin, a putative biomarker of endometrial function, is decreased in women with early pregnancy loss. Insulin-like growth factor-binding protein-1 may also play an important role in pregnancy by facilitating adhesion processes at the feto-maternal interface. We studied 48 women with polycystic ovary syndrome before and after 4 weeks of administration of 500 mg metformin (n = 26) or placebo (n = 22) 3 times daily. Oral glucose tolerance tests were performed, and serum glycodelin and insulin-like growth factor-binding protein-1 were measured during the follicular and clomiphene-induced luteal phases of menses. In the metformin group, the mean (+/-SE) area under the serum insulin curve after glucose administration decreased from 62 +/- 6 to 19 +/- 2 nmol/L.min (P < 0.001). Follicular phase serum glycodelin concentrations increased 20-fold from 150 +/- 46 to 2813 +/- 1192 pmol/L (P < 0.001), and serum insulin-like-growth factor-binding protein-1 concentrations increased from 936 +/- 152 to 2396 +/- 300 pmol/L (P < 0.001). Similarly, luteal phase serum glycodelin concentrations increased 3-fold from 3434 +/- 1299 to 10624 +/- 1803 pmol/L (P < 0.001), and serum insulin-like growth factor-binding protein-1 concentrations increased from 1220 +/- 136 to 4916 +/- 596 pmol/L (P < 0.001). Uterine vascular penetration also increased in the metformin group, as did blood flow of spiral arteries, as demonstrated by a 20% decrease in the resistance index from 0.71 +/- 0.02 to 0.57 +/- 0.03 (P < 0.001). These variables did not change in the placebo group. We conclude that insulin reduction with metformin increases follicular and luteal phase serum glycodelin and insulin-like growth factor-binding protein-1 concentrations and enhances luteal phase uterine vascularity and blood flow in the polycystic ovary syndrome. These changes may reflect an improved endometrial milieu for the establishment and maintenance of pregnancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238496     DOI: 10.1210/jcem.86.3.7295

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

Review 1.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Lara C Morley; Thomas Tang; Ephia Yasmin; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2017-11-29

Review 2.  Genetic variants associated with insulin signaling and glucose homeostasis in the pathogenesis of insulin resistance in polycystic ovary syndrome: a systematic review.

Authors:  Bhaskar Venkata Kameswara Subrahmanya Lakkakula; Maheswari Thangavelu; Usha Rani Godla
Journal:  J Assist Reprod Genet       Date:  2013-06-22       Impact factor: 3.412

3.  ROLE OF INSULIN SENSITIZERS ON CARDIOVASCULAR RISK FACTORS IN POLYCYSTIC OVARIAN SYNDROME: A META-ANALYSIS.

Authors:  Tina K Thethi; Bonnie Katalenich; Prathima Nagireddy; Pankdeep Chabbra; Nitesh Kuhadiya; Vivian Fonseca
Journal:  Endocr Pract       Date:  2015-02-25       Impact factor: 3.443

4.  Proinflammatory environment and role of TNF-α in endometrial function of obese women having polycystic ovarian syndrome.

Authors:  L Oróstica; I Astorga; F Plaza-Parrochia; C Vera; V García; R Carvajal; F Gabler; C Romero; M Vega
Journal:  Int J Obes (Lond)       Date:  2016-08-29       Impact factor: 5.095

Review 5.  Metformin in polycystic ovary syndrome: systematic review and meta-analysis.

Authors:  Jonathan M Lord; Ingrid H K Flight; Robert J Norman
Journal:  BMJ       Date:  2003-10-25

Review 6.  The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.

Authors:  Niki Katsiki; Eleni Georgiadou; Apostolos I Hatzitolios
Journal:  Drugs       Date:  2009-07-30       Impact factor: 9.546

7.  Molecular cloning and tissue-specific, developmental-stage-specific, and hormonal regulation of IGFBP3 gene in zebrafish.

Authors:  Jyh-Yih Chen; Jian-Chyi Chen; Wei-Tung Huang; Cheng-Wen Liu; Cho-Fat Hui; Thomas T Chen; Jen-Leih Wu
Journal:  Mar Biotechnol (NY)       Date:  2003-11-12       Impact factor: 3.619

Review 8.  Insulin resistance/hyperinsulinemia and reproductive disorders in infertile women.

Authors:  Tetsurou Sakumoto; Yoshimitu Tokunaga; Hideaki Tanaka; Makoto Nohara; Emi Motegi; Tadahiko Shinkawa; Aritoshi Nakaza; Masahiro Higashi
Journal:  Reprod Med Biol       Date:  2010-09-07

Review 9.  AMPK activation--protean potential for boosting healthspan.

Authors:  Mark F McCarty
Journal:  Age (Dordr)       Date:  2013-11-19

Review 10.  The Role of Hox Genes in Female Reproductive Tract Development, Adult Function, and Fertility.

Authors:  Hongling Du; Hugh S Taylor
Journal:  Cold Spring Harb Perspect Med       Date:  2015-11-09       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.